Panavir - instructions for use, dose, side effects, contraindications

Active substancePolysaccharides of shoots Solanum tuberosumPolysaccharides of shoots Solanum tuberosum

Similar drugsTo uncover

Panavir®

suppositories rect.

NATIONAL RESEARCH COMPANY, LTD. Russia

Panavir®

gel locally externally

NATIONAL RESEARCH COMPANY, LTD. Russia

Panavir®

suppositories the vagina.

NATIONAL RESEARCH COMPANY, LTD. Russia

Panavir®

solution in / in

NATIONAL RESEARCH COMPANY, LTD. Russia

Dosage form: & nbspsolution for intravenous administration

Composition:

1 ampoule (vial) contains:

active substance: Panavir® (polysaccharides of shoots Solanum tuberosum) 200 μg;

Excipients: sodium chloride 0.045 g, water for injection up to 5 ml.

Description:

Transparent or slightly opalescent, colorless or with a light brown tinge, odorless liquid.

Pharmacotherapeutic group:antiviral agent of plant origin

ATX: & nbsp

J.05.A.X Other antiviral drugs

Pharmacodynamics:

Panavir® purified shoot extract Solarium tuberosum, the main active substance is a hexose glycoside, consisting of glucose, rhamnose, arabinose, mannose, xylose, galactose, uronic acids.

The drug Panavir® is an antiviral and immunomodulating agent.

Increases the nonspecific resistance of the organism to various infections and promotes the induction of alpha interferons and gamma-leukocytes of blood.

In therapeutic doses, the drug is well tolerated.

The tests showed no mutagenic, teratogenic, carcinogenic, allergic and embryotoxic effects. In preclinical studies on laboratory animals, negative effects on reproductive function and fetal development have not been established.

It has anti-inflammatory properties in experimental models of exudative edema, chronic proliferative inflammation and in a pseudoallergic inflammatory reaction test for concanavalin A.

An analgesic effect is shown on the models of neurogenic pain and pain caused by the inflammatory process and thermal stimulation.

It has antipyretic effect.

The neuroprotective properties are shown on the model of Parkinsonian syndrome caused by systemic administration of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

Has the ability to improve the functions of the retina and optic nerve.

It has wound-healing properties in conditions of the model of stomach ulcers.

Pharmacokinetics:

When administered intravenously, polysaccharides are found in the blood 5 min after injection, are captured (by the cells of the reticuloendothelial system of the liver and spleen.) The excretion begins quickly, after 20-30 min the polysaccharides are found in urine and exhaled air.

Indications:

- Herpesvirus infections of various locations (including recurrent genital herpes, herpes zoster and ophthalmoherpes);

- secondary immunodeficiency states against the background of infectious diseases;

- cytomegalovirus infection, including in patients with habitual miscarriage;

- It is used in women with chronic viral infection and interferon-deficient state during the preparation for pregnancy;

- chronic cytomegalovirus infection in the acute stage of pregnancy in II and III trimester as part of complex therapy;

- papillomavirus infection (anogenital warts) as part of complex therapy;

- peptic ulcer of the stomach and duodenum in patients with long-term cicatrizing ulcers and symptomatic ulcers of the gastroduodenal zone as part of complex therapy;

- tick-borne encephalitis in order to reduce the viral load and relieve neurological symptoms (anisoreflexia, decreased reflexes, painful points of the exit of the cranial nerves, nystagmus) as part of complex therapies;

- rheumatoid arthritis, combined with herpesvirus infection in immunocompromised patients (to enhance analgesic and anti-inflammatory effect of basic therapy) as part of complex therapy;

- ARVI and influenza as part of complex therapy;

- Panavir® is used in the complex therapy of chronic bacterial prostatitis.

Contraindications:

- Individual intolerance. Panavir® should not be used for patients with allergies to the component components of the drug: glucose, mannose, rhamnose, arabinose, xylose;

- lactation period;

- Children under 12 years old.

Pregnancy and lactation:

Application is possible in II and III trimester according to the indication of chronic cytomegalovirus infection in the acute stage as part of complex therapy. In other cases, the application is only possible if the intended benefit to the mother exceeds the potential risk to the fetus.

If you need to use the drug during lactation, breastfeeding for the period of taking the drug should be discontinued.

Dosing and Administration:

Panavir® should be injected intravenously slowly.

The therapeutic dose of the drug is 200 μg of active substance (the contents of one ampoule or vial).

- For the treatment of herpesvirus infections and tick-borne encephalitis apply twice with an interval of 48 or 24 hours. If necessary, the course of treatment can be repeated after 1 month.

- For the treatment of cytomegalovirus and papillomavirus infections are used three times during the first week with an interval of 48 hours and twice during the second week with an interval of 72 hours.

- For treatment of chronic cytomegalovirus infection in the stage of exacerbation in pregnant women in the II and III trimester apply three times during the first week with an interval of 48 hours and twice during the second week with an interval of 72 hours.

- To treat peptic ulcer of the stomach and duodenum in the phase of exacerbation and symptomatic ulcers of the gastroduodenal zone, 5 intravenous injections every other day for 10 days are used.

- For the treatment of rheumatoid arthritis,combined with herpesvirus infection in immunocompromised patients, use 5 intravenous injections at intervals of 24-48 hours, if necessary, repeat the course after 2 months.

- For treatment of acute respiratory viral infections and influenza 2 intravenous injections are used with an interval of 18-24 hours.

- For the treatment of patients with chronic bacterial prostatitis, 5 intravenous injections are used at intervals of 48 hours.

Side effects:

The drug is well tolerated, possible complications can be associated with

individual intolerance and hypersensitivity to the components of the drug.

However, if there are any undesirable side effects, stop the injection and consult a doctor.

If you notice any other side effects not listed in the instructions, inform the doctor about it.

Overdose:

Cases of overdose are not registered.

The results of preclinical studies indicate a low toxicity of the drug.

Interaction:

Not registered.

Special instructions:

When used at the stage of preparation for pregnancy, it helps to reduce the frequency of reproductive losses in cytomegalrhvirus and herpesvirus infections.

If the solution becomes cloudy, the drug is considered to be unsuitable for use.

Effect on the ability to drive transp. cf. and fur:

Data on the possible adverse effects of the drug on the ability to drive vehicles and implement potentially hazardous activities that require special attention and speed of psychomotor reactions are lacking.

Form release / dosage:Solution for intravenous administration, 0.04 mg / ml.

Packaging:

For 5 ml of the solution in ampoules or bottles of neutral glass with a capacity of 5 ml, sealed with rubber stoppers with the rolling of aluminum caps.

For 2 or 5 ampoules in a planar cell pack, 1 contour pack of 2 or 5 ampoules, 2 contour packs of 5 ampoules together with the instructions for use and a knife ampoule or scarifier in a pack of cardboard.

When packing in ampoules with the application of a colored dot and a notch or a colored ring, the fracture on the ampoule, the scarifier or knife ampoule is not inserted.

For 2 or 5 vials in a planar cell pack, 1 contour pack of 2 or 5 bottles, 2 contour packs of 5 bottles together with instructions for use in a pack of cardboard.

Storage conditions:

In the dark place at a temperature of 2 to 25 ° C.

Keep out of the reach of children.

Shelf life:

5 years.

Do not use after the expiration date.

Terms of leave from pharmacies:On prescription

Registration number:P N000299 / 02

Date of registration:07.11.2011

The owner of the registration certificate:NATIONAL RESEARCH COMPANY, LTD. NATIONAL RESEARCH COMPANY, LTD. Russia

Manufacturer: & nbsp

MC ELLARA, LLC Russia

ELLARA, LTD. Russia

MOSHIMFARM PREPARATES them. NA Semashko OJSC Russia

Information update date: & nbsp26.08.2015

Illustrated instructions

Instructions

Panavir® (Panavir®)